Your browser doesn't support javascript.
loading
Comprehensive literature review of randomized clinical trials examining novel treatment advances in patients with colon cancer.
Skelton, William Paul; Franke, Aaron J; Iqbal, Atif; George, Thomas J.
Afiliación
  • Skelton WP; Division of Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Florida, USA.
  • Franke AJ; Division of Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Florida, USA.
  • Iqbal A; Section of Colorectal Surgery, Baylor College of Medicine, Houston, USA.
  • George TJ; Division of Hematology & Oncology, Department of Medicine, University of Florida College of Medicine, Florida, USA.
J Gastrointest Oncol ; 11(4): 790-802, 2020 Aug.
Article en En | MEDLINE | ID: mdl-32953161
ABSTRACT
The treatment of colon cancer has had numerous recent advances, in terms of surgical approach, adjuvant therapies, and more. In this review, the authors examine randomized clinical trials comparing open surgery to laparoscopic surgery (including total mesocolic excision), and also examine the role of robotic surgery. Novel surgical techniques including the no-touch technique, side-to-side anastomosis, suture technique, complete mesocolic excision (CME) with central vascular ligation (CVL), and natural orifice transluminal endoscopic surgery (NOTES) are outlined. The role of placing endoscopic self-expandable metal stents (SEMS) for colonic obstruction is compared and contrasted with the surgical approach, and the effect that the anti-VEGF inhibitor bevacizumab may have on this side effect profile is further explored. The role of the resection of the primary tumor in the setting of metastatic disease is examined with respect to survival benefit. Pathways of perioperative care which can accelerate post-surgical recovery, including enhanced recovery after surgery (ERAS) are examined. The role of adjuvant chemotherapy in patients with high-risk stage II and patients with stage III disease is examined, along with the role on circulating tumor DNA (ctDNA) as well as with the biologic targeted agents cetuximab and bevacizumab. Lastly, the authors detail the postoperative surveillance schedules after surgical resection with respect to survival outcomes.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: J Gastrointest Oncol Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: J Gastrointest Oncol Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos